On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for idiopathic pulmonary fibrosis.
After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease.
On Tuesday, Oorja Bio launched …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A new ranking of pharma companies by R&D performance
Amplia takes aim at billion-dollar pancreatic cancer drug market
Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
In this week’s edition of InnovationRx, we look at Town Hall Ventures’ $440 million haul, the CDC’s “Friday night massacre,”…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.
